EU green light for Novartis’ Rydapt
The European Commission has approved Novartis’ Rydapt to treat a certain form of acute myeloid leukaemia (AML) as well as three other rare diseases.
Read More
Tag: SM
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
